Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, starts 2016 having reached the important milestone of 50 tenants. The most recent of these is the Apollo Therapeutics Fund, launched today1, which will be based on the campus. Already recognised as one of the UK life sciences sector's most compelling locations for scientific excellence and company growth, 2016 is an important year for SBC as it continues to expand and plan for Phase 2 of its development.

Other new laboratory-based tenants include Cyclogenix (plant microprotein scaffolds for discovery of therapeutic proteins and delivery agents), Nuclera Nucleics (next generation synthesis of long DNA) and Tusk Therapeutics (immune modulators based on NK cell biology). Investment into SBC tenants now stands at over £100m.

Key activities to take place during the year include completion of fit-out in the Accelerator building, ready for the arrival of MRC Technology (MRCT) and other tenants. In addition, the Cell Therapy Catapult's £55m cell and gene therapy manufacturing centre, construction of which was initiated at the end of last year, will continue to take shape ready for opening in 2017. The Apollo Therapeutics Fund's Drug Discovery Team will also become established at SBC during 2016.

Martino Picardo, CEO of Stevenage Bioscience Catalyst, said, 'We are delighted to start 2016, our fifth year of operation, with 50 diverse and high quality tenants. Newly launched Apollo Therapeutics Fund, which is fully aligned with our focus on translation and collaboration, is another welcome addition to the campus, and we look forward to working with it. These and other developments mean that SBC will continue to generate economic growth, drive company scale-up and catalyse advances in healthcare in the future.'